Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Sunovion presents the discovery of novel selective mGlu5 PAMs

Dec. 11, 2013

Novel CB2 agonists demonstrate efficacy in animal models of inflammatory pain

Dec. 11, 2013

ImQuest BioSciences presents a novel anti-HIV microbicide gel

Dec. 11, 2013

Development of novel 5-HT2C PAMs for neurological disorders

Dec. 10, 2013

First-in-human phase I study reported for SGN-CD19A

Dec. 10, 2013

Characterization of novel cocaine metabolizing enzymes for treatment of addiction

Dec. 10, 2013

Phase Ib data for MP-4-CO in patients with sickle cell anemia

Dec. 9, 2013

MUC-1 cancer vaccine well tolerated in phase I study

Dec. 9, 2013

Novel V1B receptor antagonists demonstrate activity in animal models of anxiety and depression

Dec. 9, 2013

Novel muscarinic M4 positive allosteric modulator for the treatment of Huntington's disease

Dec. 5, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....